Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by MaaT Pharma

< Previous 1 2 Next >
MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease
From MaaT Pharma
Via Business Wire
CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting
From MaaT Pharma
Via Business Wire
MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
From MaaT Pharma
Via Business Wire
MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD
From MaaT Pharma
Via Business Wire
MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes
From MaaT Pharma
Via Business Wire
MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease
From MaaT Pharma
Via Business Wire
MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update
From MaaT Pharma
Via Business Wire
MaaT Pharma To Present and Participate in Investor and Medical Conferences in September
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16
From MaaT Pharma
Via Business Wire
MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer
From MaaT Pharma
Via Business Wire
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024
From MaaT Pharma
Via Business Wire
MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event
From MaaT Pharma
Via Business Wire
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont/ Groupe Société Générale
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview
From MaaT Pharma
Via Business Wire
MaaT Pharma Strengthens Executive Team Appointing Jonathan Chriqui as Chief Business Officer
From MaaT Pharma
Via Business Wire
MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To improve Patients’ Responses to Immunotherapies
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference
From MaaT Pharma
Via Business Wire
MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
From MaaT Pharma
Via Business Wire
MaaT Pharma to Host Virtual KOL Event on MaaT013 and MaaT033 Following ASH 2023 Presentations
From MaaT Pharma
Via Business Wire
MaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023
From MaaT Pharma
Via Business Wire
MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan
From MaaT Pharma
Via Business Wire
MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033 at the Upcoming ASH Conference
From MaaT Pharma
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback